Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 4
Submit an article Journal homepage
211
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents

Harsh Shaha Huntsman Cancer Center, University of Utah, Salt Lake City, UT, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6054-5238
ORCID Icon,
Hyejeong Jangb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Paramveer Singhb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Jorgena Kostib Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Andrew Kinb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Asif Alavib Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Voravit Ratanatharathornb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Lois Ayashb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Joseph Ubertib Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
,
Radhakrishnan Ramchandrenc Division of Hematology/Oncology University of Tennessee, Knoxville, TN, USA
,
Seongho Kimb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
&
Abhinav Deolb Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
 show all
Pages 813-820 | Received 13 Jul 2021, Accepted 26 Oct 2021, Published online: 15 Nov 2021

  • Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598–1607.
  • André MPE, Girinsky T, Federico M, et al. Early positron emission tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786–1794.
  • Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with Early-Stage hodgkin's lymphoma. N Engl J Med. 2010;363(7):640–652.
  • Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429.
  • Press OW, Li H, Schöder H, et al. US intergroup trial of Response-Adapted therapy for stage III to IV hodgkin lymphoma using early interim Fluorodeoxyglucose-Positron emission tomography imaging: Southwest oncology group S0816. J Clin Oncol. 2016;34(17):2020–2027.
  • Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive hodgkin's disease: a randomised trial. The Lancet. 2002;359(9323):2065–2071.
  • Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory hodgkin lymphoma: results of a large multicenter study of the german hodgkin lymphoma study group (GHSG). Ann Oncol. 2005;16(1):116–123.
  • Arai S, Fanale M, DeVos S, et al. Defining a hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531–2533.
  • Moskowitz AJ, Perales M-A, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory hodgkin lymphoma. Br J Haematol. 2009;146(2):158–163.
  • Milgrom SA, Jauhari S, Plastaras JP, et al. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 2017;123(8):1363–1371.
  • Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
  • Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended Follow-Up of the multicohort Single-Arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439.
  • Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory hodgkin lymphoma. Blood. 2015;125(8):1236–1243.
  • LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory hodgkin lymphoma. Blood. 2018;132(1):40–48.
  • Herrera AF, Chen RW, Palmer J, et al. PET-Adapted nivolumab or nivolumab plus ICE as first salvage therapy in relapsed or refractory hodgkin lymphoma. Blood. 2019;134(Supplement_1):239–239.
  • Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory hodgkin lymphoma. Blood. 2018;131(11):1183–1194.
  • Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with hodgkin lymphoma. Blood. 2012;119(7):1665–1670.
  • Moskowitz AJ, Shah G, Schöder H, et al. Phase II study of pembrolizumab plus GVD as Second-Line therapy for relapsed or refractory classical hodgkin lymphoma. Blood. 2020;136(Supplement 1):17–18.
  • Cheson BD, Pfistner B, Juweid ME, et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
  • Cheson BD, Ansell S, Schwartz L, et al. Refinement of the lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas. NCI Sponsored International Working GroupJ Clin Oncol. 1999;17(4):1244–1244.
  • Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017;92(9):879–884.
  • Badar T, Epperla N, Szabo A, et al. Trends in postrelapse survival in classic hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4(1):47–54.
  • Juweid ME, Cheson BD. Positron-Emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354(5):496–507.
  • Bar Ad V, Paltiel O, Glatstein E. Radiotherapy for early-stage hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials. Int J Radiat Oncol Biol Phys. 2008;72(5):1472–1479.
  • Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in hodgkin lymphoma: a systematic review and Meta-analysis. Bone Marrow Transplant. 2016;51(4):521–528.
  • Cheson BD, Fisher RI, Barrington SF, et al.; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23(21):4652–4661.
  • Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427–438.,
  • Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as Second-Line therapy for relapsed or refractory classical hodgkin lymphoma. J Clin Oncol. 2021;39(28):3109–3117.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.